TTOO (T2 Biosystems) 1-Year Sharpe Ratio: 0.73 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TTOO T2 Biosystems Inc TTOO
12 GF Score
Price $0.00
View Full Analysis

What is T2 Biosystems 1-Year Sharpe Ratio?

T2 Biosystems TTOO 12 1-Year Sharpe Ratio is 0.73 as of Jul. 19, 2026. GuruFocus rates TTOO with a GF Score™ of 12/100.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-19), T2 Biosystems's 1-Year Sharpe Ratio is 0.73.

T2 Biosystems  (OTCPK:TTOO) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

T2 Biosystems 1-Year Sharpe Ratio Related Terms

TTOO vs IDTA, NSTM, TMO: 1-Year Sharpe Ratio Comparison

For the Diagnostics & Research subindustry, T2 Biosystems's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

T2 Biosystems 1-Year Sharpe Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, T2 Biosystems's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where T2 Biosystems's 1-Year Sharpe Ratio falls into.


TTOO
12GF Score
T2 Biosystems Inc TTOO
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

T2 Biosystems 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 0.73 mean?
T2 Biosystems (TTOO) has a 1-Year Sharpe Ratio of 0.73 as of Jul. 19, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for T2 Biosystems and its competitors.
Is T2 Biosystems' 1-Year Sharpe Ratio too high?
T2 Biosystems' current 1-Year Sharpe Ratio is 0.73. Overall, T2 Biosystems has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does T2 Biosystems' 1-Year Sharpe Ratio compare to IDTA and NSTM?
T2 Biosystems' 1-Year Sharpe Ratio of 0.73 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Diagnostics & Research company?
A good 1-Year Sharpe Ratio depends on the Medical Diagnostics & Research industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for T2 Biosystems and its competitors. T2 Biosystems's current 1-Year Sharpe Ratio is 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is T2 Biosystems stock overvalued right now?
T2 Biosystems (TTOO) has a current 1-Year Sharpe Ratio of 0.73. The current 1-Year Sharpe Ratio is 0.73. T2 Biosystems' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For T2 Biosystems (TTOO), the current 1-Year Sharpe Ratio is 0.73 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

T2 Biosystems Business Description

Address 101 Hartwell Avenue, Lexington, MA, USA, 02421
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.
12GF Score

Get the complete analysis for TTOO

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price